Aratana Therapeutics Inc (NASDAQ:PETX) shares were falling nearly 18% on the heels of Friday’s announcement revealing that Entyce, approved in the U.S.
Aratana Therapeutics Inc (NASDAQ:PETX) investors are wildly disappointed today after the pet medicine maker provided a corporate update as follows: The Company now anticipates that …
Post-operative pain drug Nocita expected to begin generating widespread sales, says William Blair
